ALGS

Aligos Therapeutics, Inc. Common Stock

$5.23

Current Price

All

AI analysis

Read what the AI thinks of Aligos Therapeutics, Inc. Common Stock in the app.

Analyses are generated by AI from public data and are not investment advice.

Get the app

Key figures

Dividend per share

—

Yield

—

EPS

-$7.31

P/E

—

Data as of Oct 8

Why it matters for the long term

Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.

Upcoming events

Quarterly earnings

Expected EPS: -$2.21

Nov 4

Posts

No posts about ALGS yet.

About Aligos Therapeutics, Inc. Common Stock

ALGS is a small US biotechnology company that develops drugs, with a focus on treating viral and liver diseases. It has no big product on the market, so it earns little revenue and pays for its research with cash raised from investors and with money from partnerships. The business only pays off if its experimental drugs pass clinical trials and win approval.